Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or chemotherapy (Abstract CT086).
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women w...
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed prelimina...
Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced ...
Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation...
Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number o...